High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
17.29M
-6.36%
-0.343
-22.2%
20.98M
+13.57%
-0.292
-44.74%
22.28M
+20.68%
-0.275
-27.69%
Estimates Revision
The market is revising Downward the revenue expectations for AVITA Medical, Inc. (RCEL) for FY2025, with the revenue forecasts being adjusted by -7.35% over the past three months. During the same period, the stock price has changed by -16.67%.
Revenue Estimates for FY2025
Revise Downward
-7.35%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
+42.84%
In Past 3 Month
Stock Price
Go Down
-16.67%
In Past 3 Month
5 Analyst Rating
Wall Street analysts forecast RCEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RCEL is 8.38 USD with a low forecast of 3.00 USD and a high forecast of 14.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
2 Hold
0 Sell
Moderate Buy
Current: 3.550
Low
3.00
Averages
8.38
High
14.00
Current: 3.550
Low
3.00
Averages
8.38
High
14.00
BTIG
Sell -> Neutral
upgrade
2025-11-20
Reason
BTIG
Price Target
2025-11-20
upgrade
Sell -> Neutral
Reason
BTIG upgraded Avita Medical to Neutral from Sell with no price target following Q3 results and the CEO change that occurred as a result. Shares are down about 71% year-to-date and the firm thinks the company's "wounds are starting to heal or at least cannot get materially much worse," the analyst tells investors. While the firm shares are not quite at a place where it can recommend them, it adds that it is not inclined to recommend selling anymore either.
Lake Street
Hold
downgrade
$4 -> $3
2025-11-07
Reason
Lake Street
Price Target
$4 -> $3
2025-11-07
downgrade
Hold
Reason
Lake Street lowered the firm's price target on Avita Medical to $3 from $4 and keeps a Hold rating on the shares. The firm remains on the sidelines until seeing sales stabilization and reacceleration and a more permanent financial solution to the balance sheet, the analyst tells investors in a post-earnings note.
TD Cowen
Buy
downgrade
$8
2025-10-20
Reason
TD Cowen
Price Target
$8
2025-10-20
downgrade
Buy
Reason
TD Cowen lowered the firm's price target on Avita Medical to $5.50 from $8 and keeps a Buy rating on the shares. The firm noted Avita Medical is moving through a leadership transition, but the interim CEO is an industry veteran who will focus on a Board-backed plan centered on execution. The roughly $17M preliminary 3Q revenue result underscores that reimbursement friction was real and lasted longer than hoped, but management believes the policy side is largely fixed exiting 3Q.
Lake Street
Frank Takkinen
Buy
to
Hold
downgrade
$8 -> $4
2025-10-17
Reason
Lake Street
Frank Takkinen
Price Target
$8 -> $4
2025-10-17
downgrade
Buy
to
Hold
Reason
Lake Street analyst Frank Takkinen downgraded Avita Medical to Hold from Buy with a price target of $4, down from $8. Q3 revenue did not rebound as anticipated and Jim Corbett resigned as CEO, with Chairman Cary Vance assuming the role as interim CEO, the analyst says. The firm is downgrading shares given the Q3 shortfall, a likely guidance reset, and OrbiMed debt requiring amendments, the analyst noted.
Lake Street
Buy
to
Buy
downgrade
$14 -> $8
2025-08-11
Reason
Lake Street
Price Target
$14 -> $8
2025-08-11
downgrade
Buy
to
Buy
Reason
Lake Street assumed coverage of Avita Medical with a Buy rating and a price target of $8, down from $14. Although guidance was cut materially, the company reiterated confidence in a second half recovery and the firm views this as "a prudent reset rather than a structural impairment," the analyst tells investors.
BTIG
Neutral -> Sell
downgrade
$3
2025-08-08
Reason
BTIG
Price Target
$3
2025-08-08
downgrade
Neutral -> Sell
Reason
BTIG downgraded Avita Medical to Sell from Neutral with a $3 price target. The company reported another quarterly miss and has reduced guidance in five of the last last quarters, the analyst tells investors in a research note. The firm believes Avita is in a "very challenging position" as reimbursement to providers via Medicare Administrative Contractors were not being paid despite submitting claims for usage through the the first half of 2025. BTIG sees Recell demand continuing to drop as providers avoid risk of not being paid. It believes the shares have downside risk as Avita works to remain solvent.
See All Ratings
Valuation Metrics
The current forward P/E ratio for AVITA Medical Inc (RCEL.O) is -3.04, compared to its 5-year average forward P/E of -4.32. For a more detailed relative valuation and DCF analysis to assess AVITA Medical Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-4.32
Current PE
-3.04
Overvalued PE
10.09
Undervalued PE
-18.73
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
15.18
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
106.71
Undervalued EV/EBITDA
-76.36
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
6.45
Current PS
0.00
Overvalued PS
11.66
Undervalued PS
1.24
Financials
Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 534.61% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
RCEL News & Events
Events Timeline
(ET)
2025-12-04
12:10:00
Regencell Bioscience Shares Rise 23.7% to $16.09
2025-11-06 (ET)
2025-11-06
18:16:50
Avita Medical announces Q3 earnings per share of 46 cents, surpassing consensus estimate of 45 cents.
2025-11-03 (ET)
2025-11-03
08:36:32
Avita Medical to Present RECELL System at SRBC in Two Sessions
Sign Up For More Events
Sign Up For More Events
News
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/20251204062118_3ecbde7aba7823e486bd5d6940241723.jpeg)
Preview
7.0
12-04GlobenewswireAgilon Health CEO Resignation Triggers 27% Stock Drop
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/ea33ca3e1f2f1c0e25c21f2583e164f758043e8aecb70d479c233d1b6594c523.png)
Preview
6.0
11-21BenzingaNasdaq Analyst Becomes Optimistic; Check Out the Top 5 Upgrades for Thursday
![[object Object]](https://d5bp8bijhhba2.cloudfront.net/image/cover_image/86eb82429fb80ee7fee75d6c5144bd1d1905fed5bb8a26e4e02757f9b50589e6.png)
Preview
7.0
11-18GlobenewswireBragar Eagel & Squire, P.C. Urges Agilon, Soleno, Avita, and Coty Investors to Reach Out About Current Investigations
Sign Up For More News
People Also Watch
FAQ
What is AVITA Medical Inc (RCEL) stock price today?
What is AVITA Medical Inc (RCEL)'s business?
What is the price predicton of RCEL Stock?
What is AVITA Medical Inc (RCEL)'s revenue for the last quarter?
What is AVITA Medical Inc (RCEL)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for AVITA Medical Inc (RCEL)'s fundamentals?
How many employees does AVITA Medical Inc (RCEL). have?